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Abstract
Background—In women with schizophrenia, cognition has been shown to be enhanced 
following administration of hormone therapy or oxytocin. We examined how natural hormonal 
changes across the menstrual cycle influence cognition in women with schizophrenia. We 
hypothesized that female patients would perform better on “female-dominant” tasks (verbal 
memory/fluency) and worse on “male-dominant” tasks (visuospatial) during the early follicular 
phase (low estradiol and progesterone) compared to midluteal phase (high estradiol and 
progesterone) in relation to estradiol but not progesterone.
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Methods—Fifty-four women (23 with schizophrenia) completed cognitive assessments and 
provided blood for sex steroid assays and oxytocin at early follicular (Days 2–4) and midluteal 
(Days 20–22) phases. Men were included to verify the expected pattern of sex differences on 
cognitive tests.
Results—Expected sex differences were observed on “female-dominant” and “male-dominant” 
tasks (p<0.001), but the magnitude of those differences did not differ between patients and 
controls (p=0.44). Cognitive performance did not change across the menstrual cycle on “female-
dominant” or “male-dominant” tasks in either group. Estradiol and progesterone levels were 
unrelated to cognitive performance. Oxytocin levels did not change across the menstrual cycle but 
were positively related to performance on “female-dominant” tasks in female patients only 
(p<0.05).
Conclusions—Sex differences in cognitive function are preserved in schizophrenia. Oxytocin 
levels do not change across the cycle, but relate to enhanced performance on female dominant 
tests in women. Physiological levels of oxytocin may thus have a more powerful benefit in some 
cognitive domains than estrogens in schizophrenia.
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1. Introduction
Intervention studies demonstrate a beneficial effect of short-term hormone therapy on 
clinical symptoms and cognitive performance in premenopausal women with schizophrenia 
(Akhondzadeh et al., 2003; Bergemann et al., 2008; Ghafari et al., 2013; Huerta-Ramos et 
al., 2014; Ko et al., 2006a; Kulkarni et al., 2002; 2008; 1996; Kulkarni et al., 2014; Louza et 
al., 2004). Hormone therapy was found to specifically enhance verbal memory and fluency 
in premenopausal women with schizophrenia (Ko et al., 2006a) suggesting that these 
cognitive abilities might also be influenced by endogenous hormone levels. Physiological 
levels of estradiol and progesterone are higher during the midluteal phase of the menstrual 
cycle compared to the early follicular phase and have been shown in some studies to 
influence cognitive abilities in healthy women (Hampson, 1990a, b; Hampson et al., 2014; 
Maki et al., 2002). Little is known about how these variations in endogenous levels of sex 
hormones might influence cognition in women with schizophrenia. Oxytocin may also have 
beneficial effects on cognition in schizophrenia (Feifel et al., 2012; Frost et al., 2014). 
Whether endogenous levels of oxytocin are related to cognitive performance in women with 
schizophrenia and whether there are cycle-related variations in these relationships is 
unknown. Examining these relationships in schizophrenia is important because there is an 
overlap in the cognitive abilities that are impaired in schizophrenia, that improve with 
hormone therapy in healthy women (Hogervorst and Bandelow, 2010) and in schizophrenia 
(Bergemann et al., 2008; Huerta-Ramos et al., 2014; Ko et al., 2006a), and that favor women 
over men (e.g., verbal memory)(Kramer et al., 1988).
In this study, we examined sex differences in cognition in patients with schizophrenia and 
controls, and then evaluated whether cognitive performance varies across the menstrual 
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cycle in women with and without schizophrenia in relation to levels of estradiol, 
progesterone, and oxytocin. The primary outcomes were “male” and “female” dominant 
cognitive domains that show reliable advantages in one sex compared to the other (Rubin et 
al., 2008). Women show an advantage in verbal memory, verbal fluency, visual scanning, 
and fine motor skills whereas men show an advantage in visuospatial abilities (Halari et al., 
2005; Kramer et al., 1988; 1997; Mann, 1990; McCurry, 2001; Schmidt, 2000; Snow and 
Weinstock, 1990; Weiss et al., 2003; 2006). Based on previous studies, we hypothesized that 
both patients and controls would show the expected sex differences in these cognitive 
domains and that the magnitude of those sex differences would be preserved in 
schizophrenia. We also hypothesized that female patients and controls would show 
enhancements in “female-dominant” abilities during the midluteal compared to follicular 
phase, but the opposite pattern on “male-dominant” abilities. Based on evidence in healthy 
women, we expected those changes to relate to estradiol but not progesterone. Lastly, in 
exploratory analyses, we examined the relationship between cognitive performance and 
endogenous levels of oxytocin predicting that higher levels of endogenous oxytocin would 
be positively associated with cognitive abilities more generally.
2. Methods
2.1. Participants
Participants included 50 patients (23 women) and 58 controls (31 women). Participants were 
18 to 40 years of age and spoke English as their first language. Diagnosis of schizophrenia 
or schizoaffective disorder depressed type was confirmed with a Structured Clinical 
Interview for DSM (SCID). All women were regularly menstruating (28±5days) and were 
not taking any oral contraceptives. Exclusion criteria for all participants were: history of 
head trauma or other neurological disorder; history of substance abuse/dependence, 
excluding cigarettes; high intake of phytoestrogens (≥ 3 servings of soy/day or 
supplements); and (4) conditions resulting in abnormal gonadal hormone secretion; 
significant medical illness; and use of sex hormone treatments. Controls were also excluded 
if they were taking medications known to influence the central nervous system or had an 
Axis I psychiatric disorder (based on SCID interview). Exclusion criteria for females 
included atypical menstrual cycle length (> or < 28+5days) and pregnancy/lactation within 
the previous year.
Controls were recruited from the community, and patients from outpatient clinics and 
residential facilities in the Chicago metropolitan area. Patients [schizophrenia (68%), 
schizoaffective disorder-depressed type (32%)] were clinically stable, and reported stable 
medication regimens for the prior three months. Most patients (84%) were prescribed second 
generation antipsychotics. Antipsychotic medication dosages ranged from 40–1133mg/day 
chlorpromazine equivalents (Woods, 2003) (median dosage, 400mg/day). Forty-six percent 
of patients were taking antidepressants and 4% were taking mood stabilizers. Written 
informed consent was obtained from all participants. Study procedures were approved by the 
UIC Institutional Review Board.
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2.2.1. Female-Dominant Tests—Verbal learning and memory was assessed with the 
California Verbal Learning Test (CVLT) (Delis, Kaplan, & Ober, 1987). Verbal fluency was 
assessed with phonemic, semantic, and rhyme fluency tests. On the fluency task, participants 
generated as many words as possible in 60 seconds that began with a particular letter 
(phonemic), were animals or supermarket items (semantic), or rhymed with a particular cue 
word. Parallel forms of these verbal tests were administered to minimize practice effects. 
Data for outcome measures employed are in Table 2. Processing speed was assessed with 
the WAIS-R Digit Symbol Substitution Subtest (DSST; Wechsler, 1987) and fine motor 
skills with the Grooved Pegboard Test (GPEG; Reitan and Wolfson, 1985).
Previous studies report sex differences in favor of females on verbal memory (Kramer et al., 
1988; Kramer et al., 1997), verbal fluency (Bolla et al., 1990; Halari et al., 2005; Rahman et 
al., 2003; Weiss et al., 2003; Weiss et al., 2006), DSST (Mann, 1990; McCurry, 2001; Snow 
and Weinstock, 1990), and GPEG (McCurry, 2001; Schmidt, 2000).
2.2.1. Male-Dominant Test—Visuospatial abilities were assessed using the Card 
Rotations Test (Wilson and Vandenberg, 1978). Participants view individual sample line 
drawings of a geometric figure and eight alternatives that show the sample in two or three-
dimensional rotations of the drawing. Men show an advantage on this task compared to 
women (Sanders et al., 1982).
2.4. Procedures
Participants were assessed in two separate sessions, approximately 42 days apart. Women 
were evaluated during the early follicular phase (Day 2–4; low estradiol/progesterone) and 
the midluteal phase (Day 20–22; high estradiol/progesterone), where “Day 1” was the first 
day of menstrual bleeding. As described previously, phase was validated with estradiol and 
progesterone levels using commercial kits (estradiol by double-antibody radioimmunoassay; 
progesterone by “Coat-a-Count” coated tube RIA, Diagnostic Products, Los Angeles, CA)
(Rubin et al., 2010). Serum prolactin (for determination of possible hyperprolactinemia, > 
30ng/mL) was measured using two-site immunoenzymometric assay (TOSOH Bioscience, 
CA)(sensitivity=1 ng/mL, intra-assay CV=1.5%). Phase at first session was counterbalanced 
across female participants, and testers were blind to menstrual cycle phase. Men were also 
tested in separate sessions approximately 42 days apart. Given that half the women were 
randomly assigned to follicular phase first and half to luteal phase first, half of the men were 
randomly assigned to have data from their first session reversed with that of the second 
session. This methodological approach reduces confounds related to carry over effects. 
Plasma hormone assays for free testosterone and oxytocin were performed as described 
previously (Rubin et al., 2010).
2.5. Statistical Analyses
For the first aim regarding sex differences in cognitive function, the primary outcomes of 
interest were the “female-dominant” composite z-score and the “male-dominant” score. To 
create these, raw scores on each individual cognitive test were transformed into standardized 
z-scores using data obtained from the healthy controls (males and females combined) at the 
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first cognitive assessment (selected to avoid confound of practice effects) and then averaged 
together to create a composite representing “female-dominant” cognitive abilities. To reduce 
the number of statistical comparisons, we only examined verbal memory, verbal fluency, 
processing speed, and fine motor skills composite measures to follow-up on significant 
findings. Since we only administered one “male-dominant” task, the “male-dominant” score 
was the z-score for the card rotations test. For the analysis of sex differences at Session 1, 
the two male and female scores were used in a multivariate analysis of covariance 
(MANCOVA) where group (patient, control) and sex were the between-subjects variables 
and age was the covariate.
For the second aim addressing whether “female-dominant” and “male-dominant” abilities 
change across the menstrual cycle, mixed design ANCOVAS were conducted in which 
Menstrual Phase (follicular, midluteal) was the within-subjects variable, Group and Phase 
Order (follicular-midluteal, midluteal-follicular) were the between-subjects variables, and 
age was the covariate. Phase Order was included in the analysis to control for possible 
carryover effects from low to high estradiol/progesterone conditions or vice versa 
(Hampson, 1990a, b). Parallel ANOVAs were conducted in men to examine changes in 
cognition across sessions using the same z-score approach as in the analysis of sex 
differences. To reduce the number of statistical comparisons, we only examined individual 
test scores when the “female-dominant” cognitive ability was significant.
Exploratory analyses examined the correlation between absolute endogenous hormone levels 
and cognitive performance at Session 1 which minimized influence of practice and repeated 
testing on cognitive performance.
3. Results
Patients and controls did not significantly differ on parental education or ethnicity; however, 
patients (M=30.9, SD=6.2) were three years older than controls (M=27.7, SD=6.3)(p<0.05)
(Table 1).
3.1. Sex Differences in Cognition in Schizophrenia
Table 2 provides the mean z-scores (with standard error) for the “female-dominant” 
composite score and the “male-dominant” score as a function of group and sex at Session 1. 
As expected, there was a statistically significant difference between sexes, validating the 
designation of tests as “female” or “male”, F (2, 102)=10.79, p<0.001, Wilk’s ∧ =0.82. 
Follow-up analyses indicated that women (patients and controls) showed an advantage on 
the “female-dominant” composite (p<0.01) whereas men (patients and controls) showed an 
advantage on the “male-dominant” score (p<0.05). Of the “female-dominant” tests, women 
showed an advantage on all measures (p’s<0.05) except the verbal fluency composite 
(p=0.44). There was no significant Group x Sex interaction indicating that the magnitude of 
the sex difference did not differ across patients and controls, F (2, 102)=0.81, p=0.45, 
Wilk’s ∧ =0.98. As expected, patients performed more poorly than controls, F (2, 
102)=28.98, p<0.001, Wilk’s ∧ =0.63.
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3.2. Changes in Sex Hormones and Sexually Dimorphic Cognitive Abilities across the 
Menstrual Cycle
As previously described (Rubin et al., 2010), estradiol and progesterone levels were 
significantly higher during the midluteal versus follicular phase (p’s<0.001) whereas 
testosterone and oxytocin levels were stable across the cycle (p’s>0.48)(Table 3). 
Progesterone levels were also lower in patients compared to controls (p=0.003), but only 
during the midluteal phase (p<0.001). Despite these significant cycle-related changes in 
estradiol and progesterone, sexually dimorphic cognitive abilities did not change 
significantly across the menstrual cycle in women with or without schizophrenia (Table 4).
As previously described (Rubin et al., 2010), in men, only free testosterone levels were 
lower in male patients compared to controls (p<0.05). As expected, no hormone levels 
differed as a function of test session in males and sexually dimorphic cognitive abilities did 
not differ significantly across sessions (Table 5).
3.3. Correlational Analyses between Sex Hormones and Sexually Dimorphic Cognitive 
Abilities
At Session 1, levels of estradiol and progesterone were not associated with cognitive 
performance in women with or without schizophrenia. However, in female patients, higher 
levels of oxytocin were associated with better performance on the “female-dominant” 
composite (r=0.46, p=0.04; Figure 1), but not the male dominant test, even after controlling 
for age (r=0.52, p=0.02). A follow-up analysis of individual tests comprising the female 
composite suggested that those effects were driven by verbal memory (CVLT long delay 
free recall, r=0.45, p=0.04) and semantic fluency (r=0.46, p=0.04). Oxytocin was not 
associated with cognitive performance in female controls. There were no significant 
associations between sex hormones and the “female-dominant” composite or “male-
dominant” score in men with or without schizophrenia. A similar pattern of correlations 
were demonstrated when scores from both sessions were averaged.
4. Discussion
In the present study, we sought to examine hormonal correlates of cognitive function in 
schizophrenia by comparing performance of male and female patients and controls after 
grouping tests according to their typical sex difference. We sought to determine whether 
those sex differences are preserved in schizophrenia, change across the menstrual cycle in 
schizophrenia, and related to physiological levels of sex hormones and oxytocin. Consistent 
with findings from healthy individuals, (Halpern, 1986; Kimura and Hampson, 1993) and in 
schizophrenia (Fiszdon et al., 2003; Gur et al., 2001; Halari et al., 2006; Rubin et al., 2008; 
Sota and Heinrichs, 2003), our findings suggest that we were justified in grouping tests 
according to “female-dominant” and “male-dominant” abilities and that this pattern of sex-
related cognitive abilities is preserved in individuals with schizophrenia.
Contrary to prediction, cognitive performance was unrelated to variations in sex steroid 
hormones across the menstrual cycle in women with or without schizophrenia. The absence 
of a midluteal phase enhancement on “female-dominant” abilities and an early follicular 
enhancement on “male-dominant” abilities in the present study is consistent with a recent 
Rubin et al. Page 6













meta-analysis in healthy individuals (for a review see, Sundstrom Poromaa and Gingnell, 
2014) and in a small study of women with psychosis (Thompson et al., 2000). These 
findings suggest that these sex-related biases in cognitive ability may be established early in 
life rather than being maintained by hormone levels – at least as pertains to normal 
physiological variation in hormone levels and the magnitude of change in them that occurs 
during the menstrual cycle. Typical cycle-related changes in cognitive abilities are subtle 
and maybe influenced by genetics (Egan et al., 2001; Jacobs and D’Esposito, 2011) or 
possibly altered by other hormonal effect such as cortisol (Andreano et al., 2008; Duchesne 
and Pruessner, 2013; Espin et al., 2013).
Higher levels of oxytocin were associated with better “female-dominant” abilities in women 
with schizophrenia, although levels of estradiol and progesterone were not associated with 
cognitive performance. These findings in female patients are consistent with two studies 
from male-dominant samples of patients with schizophrenia, including a study 
demonstrating enhanced verbal learning and memory performance with adjunctive intranasal 
oxytocin (Feifel et al., 2012) and a recent study showing a positive association between 
endogenous oxytocin levels and processing speed (Frost et al., 2014). Our results suggest 
that previous findings in men may generalize to women. We did not find associations 
between endogenous oxytocin levels and verbal memory in men, perhaps men need a higher 
level of oxytocin to enhance verbal memory compared to women or alternatively perhaps 
the previous findings in male-dominant samples were driven by women. These findings also 
add to the growing literature that oxytocin in patients with schizophrenia often shows sex-
specific associations in both clinical symptom presentation and emotion perception (Rubin 
et al., 2011; Rubin et al., 2010; Strauss et al., 2015). In women with schizophrenia, oxytocin 
may confer direct benefit to “female-dominant” cognitive abilities by acting on the neural 
substrates of those abilities (e.g., hippocampus) or alternatively might benefit those 
cognitive abilities indirectly through effects on clinical symptoms.
Oxytocin is directly related to brain function and behavior, possibly via the autonomic 
nervous system (Gimpl and Fahrenholz, 2001) which regulates emotion and state (Sequeira 
et al., 2009). Conversely, estrogens effects are more global, structural, and based at least in 
part on protein synthesis; so some, but not all of estrogens influences would be expected to 
be slow (Marino et al., 2006). Oxytocin in contrast may have more direct effects and thus 
induce more rapid changes in physiological and behavior states which may underlie the 
capacity for improvements in cognitive functioning. The reason why oxytocin may have 
sex-biased effects on only “female-dominant” abilities requires further study. Assessment of 
“female-dominant” abilities was more extensive in our study, which may have enhanced our 
ability to see effects in this domain. Or, oxytocin might have a specific effect on female 
abilities as studies with other hormones have shown with supra-physiological dosing of 
hormone administration. It is noteworthy that the oxytocin effects were present in female 
patients but not controls, suggesting that a facilitative role of oxytocin on cognition may be 
more evident in cognitively compromised women with schizophrenia, which would be 
consistent with a potential therapeutic role for oxytocin therapy in the disorder.
The present study has several limitations. First, we had a limited sample size. Second, the 
“male dominant” composite included only one test, albeit assessing the domain with the 
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greatest male cognitive advantage. Future studies with a more comprehensive assessment of 
“male-dominant” skills is needed to better determine whether oxytocin has a general impact 
on cognition or one that is greater in female tasks. Third, we measured peripheral levels of 
sex steroid hormones and oxytocin. Peripheral hormone levels are imperfect markers of 
central hormone levels which may in part explain the lack of associations between 
peripheral estradiol and progesterone and cognition. While hormone levels are measurable 
in CSF (Walf et al., 2011), such studies are not always practical and are invasive. However, 
peripheral hormone levels have been shown to be related to cognitive function in menstrual 
cycle studies in healthy women (Maki et al., 2002; Mordecai et al., 2008) and in patients 
with schizophrenia (Hoff et al., 2001; Ko et al., 2006b). Finally, our focus was only on 
naturally cycling women who had regular menstrual cycles. Menstrual cycle abnormalities 
are common in females with schizophrenia, particularly among those taking antipsychotics. 
Smaller studies suggest that these abnormalities can range in patients anywhere from 26–
78% (Haddad and Wieck, 2004). Thus, it has yet to be determined whether these 
associations in women with regular cycles are generalizable to women without menstrual 
abnormalities.
5. Conclusions
In sum, the present study demonstrates that individuals with schizophrenia show expected 
sex differences in cognitive performance but this performance is unrelated to sex steroid 
hormone levels across the menstrual cycle. Our findings add to a growing literature showing 
that cognitive changes across the menstrual cycle are often difficult to detect and might not 
be as reliable as the changes in clinical symptoms and social cognition in schizophrenia 
(Rubin et al., 2011; Rubin et al., 2010). Moreover, improvements in symptoms across the 
menstrual cycle do not seem to co-occur with cognitive benefits for women with 
schizophrenia. Higher levels of oxytocin were related to enhanced performance on female 
tests in women with schizophrenia. These findings suggest that sex steroid hormones have 
limited effects in modulating sexually dimorphic cognitive abilities in premenopausal 
women with and without schizophrenia. However, oxytocin may represent a novel 
therapeutic target for not only social cognition but cognitive functioning more generally, 
particularly in women with schizophrenia. Oxytocin, but not estrogens relation to sex-biased 
cognitive abilities may have implications for cognition-enhancing treatments for 
schizophrenia, especially for female patients.
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Table 1
Demographics and Clinical Characteristics
Women Men
Patients (n = 23) Healthy Controls (n = 31) Patients (n = 27) Healthy Controls (n = 27)
Variables M (SD) M (SD) M (SD) M (SD)
Age G 30.65 (5.73) 27.55 (6.67) 31.19 (6.60) 27.93 (5.99)
Parental SES 3.00 (0.95) 3.13 (1.34) 3.14 (1.08) 3.33 (1.30)
Race, n (%)
 White, non-Hispanic 7 (31) 9 (29) 4 (15) 12 (44)
 African-American, non-Hispanic 11 (48) 14 (45) 16 (59) 8 (30)
 Hispanic or Latino 4 (17) 3 (10) 4 (15) 1 (4)
 Other 1 (4) 5 (16) 3 (11) 6 (22)
SCID diagnosis, n (%)
 Schizophrenia 13 (57) 21 (78)
 Schizoaffective (depressed type) 10 (43) 6 (22)
Duration of Illness in years† 12.96 (5.50) 11.39 (7.89)
First Generation Antipsychotics, n (%) 3 (13) 5 (19)
Second Generation Antipsychotics, n (%)
 Risperidone± 6 (26) 9 (33)
 Clozapine 2 (9) 3 (11)
 Olanzapine 3 (13) 2 (7)
 Quetiapine 3 (13) 4 (15)
 Ziprasidone 3 (13) 2 (7)
 Aripiprazole 3 (13) 2 (7)
Chlorpromazine mg equivalents S 320 (255) 484 (288)
Antipsychotic + antidepressant, n (%) 13 (56) 10 (37)
Antipsychotic + mood stabilizer, n (%) 1 (4) 1 (4)
Hyperprolactinemia,>30 ng/ml, n (%) 5 (22) 6 (24)
PANSS total score 61.51 (8.46) 65.30 (11.35)
Note. Parental SES higher scores reflect higher SES; SCID = Structured Clinical Interview for DSM; PANSS = Positive and Negative Syndrome 
Scale.
†
In years since initial treatment for psychosis.
±
Higher propensity to elevate prolactin levels compared to other second generation antipsychotics.
G
Main effect of group was significant at p<0.05.
S
Main effect of sex was significant at p<0.05.
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